(NYSE: LCI) today announced that it has commenced marketing Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, the therapeutic equivalent to the reference listed drug, Aggrenox Capsules, 25 mg/200 mg, of Boehringer Ingelheim Pharmaceuticals, Inc.
(NYSE: LCI), a company that develops, manufactures, packages, markets and distributes generic pharmaceutical products for a wide range of medical indications, announced on Tuesday that it has started marketing Aspirin and Extended-Release Dipyridamole Capsules, 25 mg/200 mg, the therapeutic equivalent to the reference listed drug, Aggrenox Capsules, 25 mg/200 mg, from Boehringer Ingelheim Pharmaceuticals Inc.
In a research note to investors, Steadman says ANI is set for several value-creating launches this year including the remaining Concerta strengths, a generic Aggrenox, a vancomycin oral solution and an undisclosed approved generic priority review product.
Other antiplatelet drugs include clopidogrel (Plavix), ticlopidine (Ticlid), dipyridamole (Persantine) and Aggrenox, a combination of dipyridamole and aspirin.
Dipyridamole Vasodilator that Indications: Mostly used inhibits cGMP in combination with phosphodiesterase and other drugs such as cellular uptake of aspirin (Aggrenox) or adenosine.
Dupont notes that antiplatelet drugs reduce the relative risk of stroke recurrence and that the combination of aspirin and dipyridamole (Aggrenox) seems to be more effective than aspirin alone.
The same is true for the temporary discontinuation of drugs such as aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs), clopidogrel (Plavix), aspirin/ extended release dipyridamole (Aggrenox), and vitamin E.
All content on this website, including dictionary, thesaurus, literature, geography, and other reference data is for informational purposes only. This information should not be considered complete, up to date, and is not intended to be used in place of a visit, consultation, or advice of a legal, medical, or any other professional.